1. Home
  2. CMND vs OGEN Comparison

CMND vs OGEN Comparison

Compare CMND & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMND
  • OGEN
  • Stock Information
  • Founded
  • CMND 2017
  • OGEN 1996
  • Country
  • CMND Canada
  • OGEN United States
  • Employees
  • CMND N/A
  • OGEN N/A
  • Industry
  • CMND Biotechnology: Pharmaceutical Preparations
  • OGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMND Health Care
  • OGEN Health Care
  • Exchange
  • CMND Nasdaq
  • OGEN Nasdaq
  • Market Cap
  • CMND 5.2M
  • OGEN 4.6M
  • IPO Year
  • CMND N/A
  • OGEN N/A
  • Fundamental
  • Price
  • CMND $0.99
  • OGEN $0.20
  • Analyst Decision
  • CMND
  • OGEN
  • Analyst Count
  • CMND 0
  • OGEN 0
  • Target Price
  • CMND N/A
  • OGEN N/A
  • AVG Volume (30 Days)
  • CMND 87.7K
  • OGEN 351.6K
  • Earning Date
  • CMND 06-12-2025
  • OGEN 05-09-2025
  • Dividend Yield
  • CMND N/A
  • OGEN N/A
  • EPS Growth
  • CMND N/A
  • OGEN N/A
  • EPS
  • CMND N/A
  • OGEN N/A
  • Revenue
  • CMND N/A
  • OGEN N/A
  • Revenue This Year
  • CMND N/A
  • OGEN N/A
  • Revenue Next Year
  • CMND N/A
  • OGEN N/A
  • P/E Ratio
  • CMND N/A
  • OGEN N/A
  • Revenue Growth
  • CMND N/A
  • OGEN N/A
  • 52 Week Low
  • CMND $0.85
  • OGEN $0.16
  • 52 Week High
  • CMND $2.30
  • OGEN $3.43
  • Technical
  • Relative Strength Index (RSI)
  • CMND 47.58
  • OGEN 52.52
  • Support Level
  • CMND $0.94
  • OGEN $0.18
  • Resistance Level
  • CMND $1.05
  • OGEN $0.22
  • Average True Range (ATR)
  • CMND 0.06
  • OGEN 0.02
  • MACD
  • CMND 0.00
  • OGEN 0.00
  • Stochastic Oscillator
  • CMND 38.22
  • OGEN 66.67

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: